Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223834 | 0.81 | BACE1 (0.50) | BACE1 | |
| SCHEMBL224676 | 0.81 | TAAR1 (0.47) | — | |
| SCHEMBL222600 | 0.81 | TAAR1 (0.47) | CYP19A1LMNANOS1NOS2 | |
| SCHEMBL3151668 | 0.80 | GFER (0.52) | MAOBMAOACYP19A1MAPTHTT | |
| SCHEMBL1753940 | 0.79 | KCNH2 (0.50) | MAOBMAOALMNARAB9ANOS1 | |
| SCHEMBL6965513 | 0.78 | PRSS1 (0.50) | — | |
| SCHEMBL224560 | 0.77 | TAAR1 (0.51) | SIGMAR1BACE1 | |
| SCHEMBL9878817 | 0.77 | HRH3 (0.46) | CYP19A1NOS1CYP11B1CYP11B2 | |
| SCHEMBL15329921 | 0.77 | MAOA (0.40) | MAOBMAOARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL223971 | 0.77 | TAAR1 (0.51) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026357-B2 | Diphenylurea compounds | LES LABORATOIRES SERVIER (FR) | 2006-04-11 | — | — | US | disclosed |
| EP-1170288-B9 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2005-01-26 | — | — | EP | disclosed |
| US-20040224993-A1 | Diphenylurea compounds | LAVIELLE GILBERT (FR) | 2004-11-11 | — | — | US | disclosed |
| US-6784183-B2 | ANTISEROTONINE AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-08-31 | — | — | US | disclosed |
| EP-1170288-B1 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | MAOB 555/4885MAOA 486/4885CYP19A1 413/4885 |
| US-20040224993-A1 | Diphenylurea compounds | HTR2C, HTR2A, HTR1A | MAOB 200/4885MAOA 246/4885CYP19A1 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.